In contrast, systemically administered neutralizing antibody, or soluble receptor, failed to restore old muscle repair.
We confirm these results in C. elegans and add a crucial control: a mutant lacking the receptor fails to respond.
In the absence of CD81, the activated B-cell receptor fails to localize correctly to lipid raft microdomains and fails to induce sustained signalling [ 44, 45].
Unlike the antibodies targeting the Met receptor, an antibody directed against the intracellular domain of epidermal growth factor receptor failed to detect any intracellular fragments.
In our hands BIIE-2046, whish is a selective antagonist of the NPY Y2 receptor, failed to affect the ghrelin induced induction of fasted motor activity.
In addition, mice carrying a targeted deletion of the estrogen receptor failed to show an increased SOCS2 expression upon estrogen stimulation [ 49].
However, bevacizumab, a monoclonal antibody against VEGF-A receptor, failed to improve PFS when combined with trastuzumab and docetaxel in a phase 3 trial compared with the non-bevacizumab arm (Gianni et al, 2013).
It was also demonstrated that GR-MR works as a specific cooperative complex to promote the binding to HRE, because cotransfection with other steroid receptor failed to show changes in HRE-luciferase expression [ 51].
However, neutralizing E272 (E272Q) did not allow for resolution of single-channel currents, either because the mutation did not increase channel conductance or because the receptor failed to express in cells.
Figure 8 highlights that the oncogenic mutants lead to the induction or increased expression of many STAT target genes whereas stimulation of the wild-type receptor fails to do so in most cases.
